

Evaluation Report for Category B, Subcategories 2.1, 2.3, 2.4, 3.4 Application

Application Number: 2020-0341
Application: New EP Product Chemistry-Guarantee, Identity of Formulants,
Proportion of Formulants
New Product Labels-Application Method
Product: Wolman MNB
Registration Number: 34048
Active ingredients (a.i.): Basic copper carbonate and tebuconazole
PMRA Document Number :3206379

Purpose of Application

The purpose of this application was to register Wolman MNB, for use as a heavy-duty wood preservative.

Chemistry Assessment

Wolman MNB is formulated as a suspension containing copper at 25.0%, present as basic copper carbonate, and tebuconazole at 1.0%. This end-use product has a density of 1.537 g/mL and pH of 8.50. The required chemistry data for Wolman MNB have been provided, reviewed and found to be acceptable.

Health Assessments

Wolman MNB is of moderate acute toxicity via the oral route, and of low acute toxicity via the dermal and inhalation routes. It is minimally irritating to the eye, slightly irritating to the skin, and is considered to be a potential dermal sensitizer.

The use of Wolman MNB as a pressure treatment application to various wood products is not expected to result in potential occupational or bystander exposure over the registered use of basic copper carbonate and tebuconazole. No health risks of concern are expected when workers follow label directions and wear personal protective equipment as stated on the label.

A food residue assessment was not required for this application.

Environmental Assessment

The uses are within the currently registered use pattern of the active ingredients, copper (present as basic copper carbonate) and tebuconazole, and therefore, no additional risk is expected from the use of Wolman MNB. The label includes the required environmental precautions and hazards statements to mitigate risks to the environment.

Value Assessment

A comparison of the formulation of Wolman MNB to the registered precedent product, and the subsequent comparison of the use patterns, demonstrated that the differences between the formulations are not likely to affect the product's efficacy. As a result, all uses on the precedent product label are acceptable to be included on the Wolman MNB product label.

Conclusion

The Pest Management Regulatory Agency has completed an assessment of the information provided, and has found the information sufficient to support the registration of Wolman MNB.

References

PMRA Document Number	References
3084074	2018, Chemistry Requirements Summary (DACO 3.1 - 3.5.15), DACO: 3.0,3.1,3.1.1,3.1.4,3.2,3.2.1,3.2.2,3.2.3,3.3.1,3.4,3.4.1,3.4.2,3.5,3.5.1,3.5.10,3.5.11,3.5.12,3.5.13,3.5.14,3.5.15,3.5.2,3.5.3,3.5.4,3.5.5,3.5.6,3.5.7,3.5.8,3.5.9 CBI
3084075	2018, Wolman MNB Formulation Process, DACO: 3.2 CBI
3084076	2014, Wolman E uCA-B 25: Physical and Chemical Characteristics: Color, Physical State, Odor, Oxidation/Reductions, pH, Viscosity, and Density/Relative Density, DACO: 3.5.1,3.5.2,3.5.3,3.5.6,3.5.7,3.5.8,3.5.9 CBI
3084077	2015, Wolman E uCA-B 25: Storage Stability and Corrosion Characteristics, DACO: 3.5.10,3.5.14
3084078	2015, Wolman E uCA-B 25: Enforcement Analytical Methods for the Determination of Tebuconazole by High Performance Liquid Chromatography and Copper by ICP-MS and Atomic Absorption, DACO: 3.4.1 CBI
3121870	2020, Wolman MNB Formulation Process, DACO: 3.2.2
3084080	2019, Wolman MNB: Acute oral Toxicity - Up-and-Down Procedure in Rats, DACO: 4.2.1
3084081	2019, Wolman MNB: Acute Dermal Toxicity in Rats, DACO: 4.2.2
3084082	2019, Wolman MNB: Acute Inhalation Toxicity in Rats, DACO: 4.2.3
3084083	2019, Wolman MNB: Primary Eye Irritation in Rabbits, DACO: 4.2.4
3084084	2019, Wolman MNB: Primary Skin Irritation in Rabbits, DACO: 4.2.5
3084085	2019, Wolman MNB: Local Lymph Node Assay (LLNA) in Mice, DACO: 4.2.6

© Her Majesty the Queen in Right of Canada, as represented by the Minister of Health Canada, 2021

All rights reserved. No part of this information (publication or product) may be reproduced or transmitted in any form or by any means, electronic, mechanical, photocopying, recording or otherwise, or stored in a retrieval system, without prior written permission of Health Canada, Ottawa, Ontario K1A 0K9.